The integration of targeted molecular imaging and therapeutic radiopharmaceuticals into clinical care has had a significant impact on the diagnosis and treatment of cancer patients. For example, the recent FDA approvals of new radiopharmaceuticals for imaging and therapy of patients diagnosed with neuroendocrine tumors or prostate cancer illustrate this momentum of the nuclear medicine field. New isotopes and the development of corresponding radiochemistry are critical to a continued expansion of these impactful techniques. In particular, theranostic strategies where similar or identical radiopharmaceuticals are used for imaging and therapy can benefit from the availability of elementally matched pairs of isotopes such as 64Cu and 67Cu. Recent advances in cyclotron targetry and radiochemistry has enabled the development of additional pairs including 43Sc/47Sc and 203Pb/212Pb. 43Sc (suitable for PET imaging) and 47Sc (suitable for therapy) can be produced via proton bombardment of Ti targets, purified using ion chromatography and complexed with a variety of chelators for radiopharmaceutical development. 203Pb (suitable for SPECT imaging) can be produced from proton bombardment of thallium targets whereas 212Pb is available through a generator system. Recent collaborative results from both radiochemistry and imaging studies will be presented.

Expanding the toolbox of radiometals for oncologic imaging and therapy

Where thousands of chemistry professionals meet to share ideas and advance scientific and technical knowledge. Spring 2023 abstracts, posters, and presentations will launch at the end of March.

ACS Spring 2023

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.